✨ Free AI Report
Lineage Cell Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Lineage Cell Therapeutics, Inc.
Company Research

Lineage Cell Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Lineage is a clinical-stage biotechnology company developing novel allogeneic, or "off-the-shelf," cell therapies for serious neurological and ophthalmic conditions. Functional cells developed from such lineages that ...

Analyst-debate audio for Lineage Cell Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Lineage Cell Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Lineage offers regenerative medicine exposure with validated partnership optionality and durable clinical signals, but...

Read the full analyst-debate transcript →
Industry Biotechnology - Cell Therapy & Regenerative Medicine
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Lineage Cell Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Lineage Cell Therapeutics, Inc. Overview

Pro stress-test →

Lineage is a clinical-stage biotechnology company developing novel allogeneic, or "off-the-shelf," cell therapies for serious neurological and ophthalmic conditions. Functional cells developed from such lineages that are relevant to the underlying condition are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or enhance the patient's functional activity.

Strategic Profile

Pro stress-test →

The company's business strategy is to efficiently leverage its technology platform and its development and manufacturing capabilities to advance its programs internally or in conjunction with strategic partners to further enhance their value and probability of success. OpRegen's uniquely durable treatment effects last up to 24 months, with a 36-month data update from Roche and Genentech forthcoming. The company received a novel, induced pluripotent stem cell (iPSC) line containing hypoimmunity edits from Factor Bioscience Inc., marking a successful milestone in their strategic collaboration.

Competitive Landscape

Pro stress-test →

Lineage specializes in developing regenerative cell-based therapies, focusing on regenerating or replacing damaged tissues using pluripotent cell technology, offering broader therapeutic potential compared to traditional drugs aimed at molecular targets. The company competes in the cell therapy and regenerative medicine space with other developers of allogeneic cell therapies, autologous therapies, and traditional pharmaceutical approaches for similar indications.

Industry Context

Lineage Cell Therapeutics, Inc. operates in Biotechnology - Cell Therapy & Regenerative Medicine.

Key facts

Founded: 1990 · Headquarters: Carlsbad, California · Revenue: $9.5M (2024) · Market cap: $225M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Lineage Cell Therapeutics, Inc..

  • Lead program OpRegen (in collaboration with Roche/Genentech) shows durable 24-month treatment durability for age-related macular degeneration, validating the retinal pigment epithelium transplant mechanism of action
  • Diversified pipeline spanning ophthalmology (OpRegen, PNC1), neurology (OPC1 for spinal cord injury), oncology (VAC2 for lung cancer), and emerging platforms reduces single-program risk
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Received novel hypoimmunity-edited iPSC line from Factor Bioscience, advancing off-the-shelf cell therapy capabilities
  • November 2025Company publishes stockholder letter highlighting 2025 achievements and 2026 corporate outlook
  • +2 moreTrack every material event for Lineage Cell Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Lineage Cell Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CAR-T cell therapy platformAutologous cell therapy for oncology→iPSC-derived cell therapiesOff-the-shelf allogeneic cell therapies→Regenerative medicine platformiPSC-derived cell replacement therapies→RPE cell replacement therapiesRetinal pigment epithelium cell therapy for AMD→

Compare Lineage Cell Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Lineage Cell Therapeutics, Inc. operates in Biotechnology - Cell Therapy & Regenerative Medicine. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Cell Therapy & Regenerative Medicine research →
NEW · MCP server

Ask your AI assistant about Lineage Cell Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Lineage Cell Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Lineage Cell Therapeutics, Inc. do this quarter?”
“Is Lineage Cell Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Lineage Cell Therapeutics, Inc. do?+
Lineage is a clinical-stage biotechnology company developing novel allogeneic, or "off-the-shelf," cell therapies for serious neurological and ophthalmic conditions. Functional cells developed from such lineages that ...
What is Lineage Cell Therapeutics, Inc.'s Cyborg Score?+
Lineage Cell Therapeutics, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Lineage Cell Therapeutics, Inc.'s main competitors?+
Named competitors include CAR-T cell therapy platform, iPSC-derived cell therapies, Regenerative medicine platform, RPE cell replacement therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Lineage Cell Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Lineage Cell Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Lineage Cell Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.